CFTR and familial pancreatic carcinoma: We show that germline testing detects a PV in 23.9% of subjects with AP or CP, including PRSS1 (4.5%) and biallelic CFTR (1.3%) which have direct implications for management (pancreatic cancer screening and cascade testing for PRSS1, testing for cystic fibrosis for biallelic CFTR).